Inhibition of brain creatine kinase activity after renal ischemia is attenuated by N-acetylcysteine and deferoxamine administration

Encephalopathy may accompany acute or chronic renal failure, and the mechanisms responsible for neurological complications in patients with renal failure are poorly known. Considering that creatine kinase (CK) is important for brain energy homeostasis and is inhibited by free radicals, and that oxid...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuroscience letters 2008-03, Vol.434 (1), p.139-143
Hauptverfasser: Di-Pietro, Priscila B., Dias, Márcia L., Scaini, Giselli, Burigo, Márcio, Constantino, Larissa, Machado, Roberta A., Dal-Pizzol, Felipe, Streck, Emilio L.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 143
container_issue 1
container_start_page 139
container_title Neuroscience letters
container_volume 434
creator Di-Pietro, Priscila B.
Dias, Márcia L.
Scaini, Giselli
Burigo, Márcio
Constantino, Larissa
Machado, Roberta A.
Dal-Pizzol, Felipe
Streck, Emilio L.
description Encephalopathy may accompany acute or chronic renal failure, and the mechanisms responsible for neurological complications in patients with renal failure are poorly known. Considering that creatine kinase (CK) is important for brain energy homeostasis and is inhibited by free radicals, and that oxidative stress is probably involved in the pathogenesis of uremic encephalopathy, we measured CK activity (hippocampus, striatum, cerebellum, cerebral cortex and prefrontal cortex) in brain if rats submitted to renal ischemia and the effect of administration of antioxidants ( N-acetylcysteine, NAC and deferoxamine, DFX) on this enzyme. We verified that CK activity was not altered in cerebellum and striatum of rats. CK activity was inhibited in prefrontal cortex and hippocampus of rats 12 h after renal ischemia. The treatment with antioxidants prevented such effect. Cerebral cortex was also affected, but in this area CK activity was inhibited 6 and 12 h after renal ischemia. Moreover, only NAC or NAC plus DFX were able to prevent the inhibition on the enzyme. Although it is difficult to extrapolate our findings to the human condition, the inhibition of brain CK activity after renal failure may be associated to neuronal loss and may be involved in the pathogenesis of uremic encephalopathy.
doi_str_mv 10.1016/j.neulet.2008.01.051
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70409670</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0304394008001213</els_id><sourcerecordid>70409670</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-4466fd2ea180df0b1e804d8670a73c156ba4b0681794fde9271d76e9056bbbe33</originalsourceid><addsrcrecordid>eNp9kU1v1DAQhi0EokvhHyDkC9wSxok3Ti5IqOKjUgUXOFtje6J6SZxiO1Vz5o_jZVdw4zSW55nX9mPGXgqoBYju7aEOtE6U6wagr0HUsBeP2E70qqnUoJrHbActyKodJFywZykdAAqyl0_ZhehLR7Vyx35dh1tvfPZL4MvITUQfuI2E2QfiP3zARBxt9vc-bxzHTJFHCjhxn-wtzR7LgmPOFFbM5LjZ-JcKLeVtslvKdIzB4LijkeLygPOfDVeKTzni8eDn7MmIU6IX53rJvn_88O3qc3Xz9dP11fubyrYD5ErKrhtdQyh6cCMYQT1I13cKULVW7DuD0kDXCzXI0dHQKOFURwOUjjHUtpfszSn3Li4_V0pZz-URNE0YaFmTViBhKHEFlCfQxiWlSKO-i37GuGkB-ihfH_RJvj7K1yB0MVvGXp3zVzOT-zd0tl2A12cAk8VpjBisT3-5Bsrn7TtVuHcnjoqNe09RJ-spWHI-ks3aLf7_N_kNqzqnZA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70409670</pqid></control><display><type>article</type><title>Inhibition of brain creatine kinase activity after renal ischemia is attenuated by N-acetylcysteine and deferoxamine administration</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Di-Pietro, Priscila B. ; Dias, Márcia L. ; Scaini, Giselli ; Burigo, Márcio ; Constantino, Larissa ; Machado, Roberta A. ; Dal-Pizzol, Felipe ; Streck, Emilio L.</creator><creatorcontrib>Di-Pietro, Priscila B. ; Dias, Márcia L. ; Scaini, Giselli ; Burigo, Márcio ; Constantino, Larissa ; Machado, Roberta A. ; Dal-Pizzol, Felipe ; Streck, Emilio L.</creatorcontrib><description>Encephalopathy may accompany acute or chronic renal failure, and the mechanisms responsible for neurological complications in patients with renal failure are poorly known. Considering that creatine kinase (CK) is important for brain energy homeostasis and is inhibited by free radicals, and that oxidative stress is probably involved in the pathogenesis of uremic encephalopathy, we measured CK activity (hippocampus, striatum, cerebellum, cerebral cortex and prefrontal cortex) in brain if rats submitted to renal ischemia and the effect of administration of antioxidants ( N-acetylcysteine, NAC and deferoxamine, DFX) on this enzyme. We verified that CK activity was not altered in cerebellum and striatum of rats. CK activity was inhibited in prefrontal cortex and hippocampus of rats 12 h after renal ischemia. The treatment with antioxidants prevented such effect. Cerebral cortex was also affected, but in this area CK activity was inhibited 6 and 12 h after renal ischemia. Moreover, only NAC or NAC plus DFX were able to prevent the inhibition on the enzyme. Although it is difficult to extrapolate our findings to the human condition, the inhibition of brain CK activity after renal failure may be associated to neuronal loss and may be involved in the pathogenesis of uremic encephalopathy.</description><identifier>ISSN: 0304-3940</identifier><identifier>EISSN: 1872-7972</identifier><identifier>DOI: 10.1016/j.neulet.2008.01.051</identifier><identifier>PMID: 18304734</identifier><identifier>CODEN: NELED5</identifier><language>eng</language><publisher>Shannon: Elsevier Ireland Ltd</publisher><subject>Acetylcysteine - pharmacology ; Acetylcysteine - therapeutic use ; Animals ; Antioxidants - pharmacology ; Antioxidants - therapeutic use ; Biological and medical sciences ; Brain - drug effects ; Brain - enzymology ; Brain - physiopathology ; Brain Diseases, Metabolic - drug therapy ; Brain Diseases, Metabolic - enzymology ; Brain Diseases, Metabolic - physiopathology ; Creatine kinase ; Creatine Kinase - antagonists &amp; inhibitors ; Creatine Kinase - metabolism ; Deferoxamine ; Deferoxamine - pharmacology ; Deferoxamine - therapeutic use ; Down-Regulation - drug effects ; Down-Regulation - physiology ; Fundamental and applied biological sciences. Psychology ; Ischemia - complications ; Kidney Diseases - complications ; Male ; N-Acetylcysteine ; Nerve Degeneration - drug therapy ; Nerve Degeneration - enzymology ; Nerve Degeneration - physiopathology ; Oxidative Stress - drug effects ; Oxidative Stress - physiology ; Rats ; Rats, Wistar ; Renal failure ; Subcellular Fractions ; Time Factors ; Treatment Outcome ; Uremia - drug therapy ; Uremia - enzymology ; Uremia - physiopathology ; Vertebrates: nervous system and sense organs</subject><ispartof>Neuroscience letters, 2008-03, Vol.434 (1), p.139-143</ispartof><rights>2008 Elsevier Ireland Ltd</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-4466fd2ea180df0b1e804d8670a73c156ba4b0681794fde9271d76e9056bbbe33</citedby><cites>FETCH-LOGICAL-c390t-4466fd2ea180df0b1e804d8670a73c156ba4b0681794fde9271d76e9056bbbe33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0304394008001213$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=20187567$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18304734$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Di-Pietro, Priscila B.</creatorcontrib><creatorcontrib>Dias, Márcia L.</creatorcontrib><creatorcontrib>Scaini, Giselli</creatorcontrib><creatorcontrib>Burigo, Márcio</creatorcontrib><creatorcontrib>Constantino, Larissa</creatorcontrib><creatorcontrib>Machado, Roberta A.</creatorcontrib><creatorcontrib>Dal-Pizzol, Felipe</creatorcontrib><creatorcontrib>Streck, Emilio L.</creatorcontrib><title>Inhibition of brain creatine kinase activity after renal ischemia is attenuated by N-acetylcysteine and deferoxamine administration</title><title>Neuroscience letters</title><addtitle>Neurosci Lett</addtitle><description>Encephalopathy may accompany acute or chronic renal failure, and the mechanisms responsible for neurological complications in patients with renal failure are poorly known. Considering that creatine kinase (CK) is important for brain energy homeostasis and is inhibited by free radicals, and that oxidative stress is probably involved in the pathogenesis of uremic encephalopathy, we measured CK activity (hippocampus, striatum, cerebellum, cerebral cortex and prefrontal cortex) in brain if rats submitted to renal ischemia and the effect of administration of antioxidants ( N-acetylcysteine, NAC and deferoxamine, DFX) on this enzyme. We verified that CK activity was not altered in cerebellum and striatum of rats. CK activity was inhibited in prefrontal cortex and hippocampus of rats 12 h after renal ischemia. The treatment with antioxidants prevented such effect. Cerebral cortex was also affected, but in this area CK activity was inhibited 6 and 12 h after renal ischemia. Moreover, only NAC or NAC plus DFX were able to prevent the inhibition on the enzyme. Although it is difficult to extrapolate our findings to the human condition, the inhibition of brain CK activity after renal failure may be associated to neuronal loss and may be involved in the pathogenesis of uremic encephalopathy.</description><subject>Acetylcysteine - pharmacology</subject><subject>Acetylcysteine - therapeutic use</subject><subject>Animals</subject><subject>Antioxidants - pharmacology</subject><subject>Antioxidants - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Brain - drug effects</subject><subject>Brain - enzymology</subject><subject>Brain - physiopathology</subject><subject>Brain Diseases, Metabolic - drug therapy</subject><subject>Brain Diseases, Metabolic - enzymology</subject><subject>Brain Diseases, Metabolic - physiopathology</subject><subject>Creatine kinase</subject><subject>Creatine Kinase - antagonists &amp; inhibitors</subject><subject>Creatine Kinase - metabolism</subject><subject>Deferoxamine</subject><subject>Deferoxamine - pharmacology</subject><subject>Deferoxamine - therapeutic use</subject><subject>Down-Regulation - drug effects</subject><subject>Down-Regulation - physiology</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Ischemia - complications</subject><subject>Kidney Diseases - complications</subject><subject>Male</subject><subject>N-Acetylcysteine</subject><subject>Nerve Degeneration - drug therapy</subject><subject>Nerve Degeneration - enzymology</subject><subject>Nerve Degeneration - physiopathology</subject><subject>Oxidative Stress - drug effects</subject><subject>Oxidative Stress - physiology</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Renal failure</subject><subject>Subcellular Fractions</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Uremia - drug therapy</subject><subject>Uremia - enzymology</subject><subject>Uremia - physiopathology</subject><subject>Vertebrates: nervous system and sense organs</subject><issn>0304-3940</issn><issn>1872-7972</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU1v1DAQhi0EokvhHyDkC9wSxok3Ti5IqOKjUgUXOFtje6J6SZxiO1Vz5o_jZVdw4zSW55nX9mPGXgqoBYju7aEOtE6U6wagr0HUsBeP2E70qqnUoJrHbActyKodJFywZykdAAqyl0_ZhehLR7Vyx35dh1tvfPZL4MvITUQfuI2E2QfiP3zARBxt9vc-bxzHTJFHCjhxn-wtzR7LgmPOFFbM5LjZ-JcKLeVtslvKdIzB4LijkeLygPOfDVeKTzni8eDn7MmIU6IX53rJvn_88O3qc3Xz9dP11fubyrYD5ErKrhtdQyh6cCMYQT1I13cKULVW7DuD0kDXCzXI0dHQKOFURwOUjjHUtpfszSn3Li4_V0pZz-URNE0YaFmTViBhKHEFlCfQxiWlSKO-i37GuGkB-ihfH_RJvj7K1yB0MVvGXp3zVzOT-zd0tl2A12cAk8VpjBisT3-5Bsrn7TtVuHcnjoqNe09RJ-spWHI-ks3aLf7_N_kNqzqnZA</recordid><startdate>20080321</startdate><enddate>20080321</enddate><creator>Di-Pietro, Priscila B.</creator><creator>Dias, Márcia L.</creator><creator>Scaini, Giselli</creator><creator>Burigo, Márcio</creator><creator>Constantino, Larissa</creator><creator>Machado, Roberta A.</creator><creator>Dal-Pizzol, Felipe</creator><creator>Streck, Emilio L.</creator><general>Elsevier Ireland Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20080321</creationdate><title>Inhibition of brain creatine kinase activity after renal ischemia is attenuated by N-acetylcysteine and deferoxamine administration</title><author>Di-Pietro, Priscila B. ; Dias, Márcia L. ; Scaini, Giselli ; Burigo, Márcio ; Constantino, Larissa ; Machado, Roberta A. ; Dal-Pizzol, Felipe ; Streck, Emilio L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-4466fd2ea180df0b1e804d8670a73c156ba4b0681794fde9271d76e9056bbbe33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Acetylcysteine - pharmacology</topic><topic>Acetylcysteine - therapeutic use</topic><topic>Animals</topic><topic>Antioxidants - pharmacology</topic><topic>Antioxidants - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Brain - drug effects</topic><topic>Brain - enzymology</topic><topic>Brain - physiopathology</topic><topic>Brain Diseases, Metabolic - drug therapy</topic><topic>Brain Diseases, Metabolic - enzymology</topic><topic>Brain Diseases, Metabolic - physiopathology</topic><topic>Creatine kinase</topic><topic>Creatine Kinase - antagonists &amp; inhibitors</topic><topic>Creatine Kinase - metabolism</topic><topic>Deferoxamine</topic><topic>Deferoxamine - pharmacology</topic><topic>Deferoxamine - therapeutic use</topic><topic>Down-Regulation - drug effects</topic><topic>Down-Regulation - physiology</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Ischemia - complications</topic><topic>Kidney Diseases - complications</topic><topic>Male</topic><topic>N-Acetylcysteine</topic><topic>Nerve Degeneration - drug therapy</topic><topic>Nerve Degeneration - enzymology</topic><topic>Nerve Degeneration - physiopathology</topic><topic>Oxidative Stress - drug effects</topic><topic>Oxidative Stress - physiology</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Renal failure</topic><topic>Subcellular Fractions</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Uremia - drug therapy</topic><topic>Uremia - enzymology</topic><topic>Uremia - physiopathology</topic><topic>Vertebrates: nervous system and sense organs</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Di-Pietro, Priscila B.</creatorcontrib><creatorcontrib>Dias, Márcia L.</creatorcontrib><creatorcontrib>Scaini, Giselli</creatorcontrib><creatorcontrib>Burigo, Márcio</creatorcontrib><creatorcontrib>Constantino, Larissa</creatorcontrib><creatorcontrib>Machado, Roberta A.</creatorcontrib><creatorcontrib>Dal-Pizzol, Felipe</creatorcontrib><creatorcontrib>Streck, Emilio L.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Neuroscience letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Di-Pietro, Priscila B.</au><au>Dias, Márcia L.</au><au>Scaini, Giselli</au><au>Burigo, Márcio</au><au>Constantino, Larissa</au><au>Machado, Roberta A.</au><au>Dal-Pizzol, Felipe</au><au>Streck, Emilio L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inhibition of brain creatine kinase activity after renal ischemia is attenuated by N-acetylcysteine and deferoxamine administration</atitle><jtitle>Neuroscience letters</jtitle><addtitle>Neurosci Lett</addtitle><date>2008-03-21</date><risdate>2008</risdate><volume>434</volume><issue>1</issue><spage>139</spage><epage>143</epage><pages>139-143</pages><issn>0304-3940</issn><eissn>1872-7972</eissn><coden>NELED5</coden><abstract>Encephalopathy may accompany acute or chronic renal failure, and the mechanisms responsible for neurological complications in patients with renal failure are poorly known. Considering that creatine kinase (CK) is important for brain energy homeostasis and is inhibited by free radicals, and that oxidative stress is probably involved in the pathogenesis of uremic encephalopathy, we measured CK activity (hippocampus, striatum, cerebellum, cerebral cortex and prefrontal cortex) in brain if rats submitted to renal ischemia and the effect of administration of antioxidants ( N-acetylcysteine, NAC and deferoxamine, DFX) on this enzyme. We verified that CK activity was not altered in cerebellum and striatum of rats. CK activity was inhibited in prefrontal cortex and hippocampus of rats 12 h after renal ischemia. The treatment with antioxidants prevented such effect. Cerebral cortex was also affected, but in this area CK activity was inhibited 6 and 12 h after renal ischemia. Moreover, only NAC or NAC plus DFX were able to prevent the inhibition on the enzyme. Although it is difficult to extrapolate our findings to the human condition, the inhibition of brain CK activity after renal failure may be associated to neuronal loss and may be involved in the pathogenesis of uremic encephalopathy.</abstract><cop>Shannon</cop><pub>Elsevier Ireland Ltd</pub><pmid>18304734</pmid><doi>10.1016/j.neulet.2008.01.051</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0304-3940
ispartof Neuroscience letters, 2008-03, Vol.434 (1), p.139-143
issn 0304-3940
1872-7972
language eng
recordid cdi_proquest_miscellaneous_70409670
source MEDLINE; Elsevier ScienceDirect Journals
subjects Acetylcysteine - pharmacology
Acetylcysteine - therapeutic use
Animals
Antioxidants - pharmacology
Antioxidants - therapeutic use
Biological and medical sciences
Brain - drug effects
Brain - enzymology
Brain - physiopathology
Brain Diseases, Metabolic - drug therapy
Brain Diseases, Metabolic - enzymology
Brain Diseases, Metabolic - physiopathology
Creatine kinase
Creatine Kinase - antagonists & inhibitors
Creatine Kinase - metabolism
Deferoxamine
Deferoxamine - pharmacology
Deferoxamine - therapeutic use
Down-Regulation - drug effects
Down-Regulation - physiology
Fundamental and applied biological sciences. Psychology
Ischemia - complications
Kidney Diseases - complications
Male
N-Acetylcysteine
Nerve Degeneration - drug therapy
Nerve Degeneration - enzymology
Nerve Degeneration - physiopathology
Oxidative Stress - drug effects
Oxidative Stress - physiology
Rats
Rats, Wistar
Renal failure
Subcellular Fractions
Time Factors
Treatment Outcome
Uremia - drug therapy
Uremia - enzymology
Uremia - physiopathology
Vertebrates: nervous system and sense organs
title Inhibition of brain creatine kinase activity after renal ischemia is attenuated by N-acetylcysteine and deferoxamine administration
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T15%3A56%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inhibition%20of%20brain%20creatine%20kinase%20activity%20after%20renal%20ischemia%20is%20attenuated%20by%20N-acetylcysteine%20and%20deferoxamine%20administration&rft.jtitle=Neuroscience%20letters&rft.au=Di-Pietro,%20Priscila%20B.&rft.date=2008-03-21&rft.volume=434&rft.issue=1&rft.spage=139&rft.epage=143&rft.pages=139-143&rft.issn=0304-3940&rft.eissn=1872-7972&rft.coden=NELED5&rft_id=info:doi/10.1016/j.neulet.2008.01.051&rft_dat=%3Cproquest_cross%3E70409670%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70409670&rft_id=info:pmid/18304734&rft_els_id=S0304394008001213&rfr_iscdi=true